Ken Griffin Annovis Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	SELL	$1.22 - $3.24 $52,216 - $138,672	-42,800 Reduced 55.8%	33,900 $73,000
Q1 2025 May 15, 2025	SELL	$1.5 - $5.39 $343,200 - $1.23 Million	-228,800 Reduced 74.89%	76,700 $115,000
Q4 2024 Feb 14, 2025	BUY	$4.37 - $9.87 $178,733 - $403,682	40,900 Added 15.46%	305,500 $1.54 Million
Q3 2024 Nov 14, 2024	BUY	$5.27 - $15.46 $667,709 - $1.96 Million	126,700 Added 91.88%	264,600 $2.13 Million
Q2 2024 Aug 14, 2024	BUY	$4.82 - $18.01 $100,256 - $374,608	20,800 Added 17.76%	137,900 $794,000
Q1 2024 May 15, 2024	BUY	$8.47 - $18.93 $972,356 - $2.17 Million	114,800 Added 4991.3%	117,100 $1.39 Million
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $12,765 - $45,126	2,300 New	2,300 $43,000

1.82M

102K

98.3K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $22.6M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.